Colistin in the intensive care unit;La colistine en réanimation

Reanimation

Volumn 17, Issue 3, 2008, Pages 251-258

  Frasca, D ^a   Dahyot Fizelier, C ^a   Mimoz, O ^a  

^a POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

Antibiotic; Colistimethate; Colistin; Nosocomial infection; Pharmacokinetics

Indexed keywords

AMIKACIN; CEFTAZIDIME; COLISTIMETHATE; COLISTIN; IMIPENEM; RIFAMPICIN; TOBRAMYCIN;

ACINETOBACTER BAUMANNII; AEROSOL; ANTIBACTERIAL ACTIVITY; BACTERIAL INFECTION; CREATININE CLEARANCE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DOSE; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; GRAM NEGATIVE AEROBIC RODS AND COCCI; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; LUNG DISEASE; MULTIDRUG RESISTANCE; NEUROTOXICITY; PSEUDOMONAS AERUGINOSA; SHORT SURVEY; ULTRAFILTRATION;

EID: 41949141319     PISSN: 16240693     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.reaurg.2008.01.005     Document Type: Short Survey

References (40)

1. Li J., Nation R.L., Milne R.W., Turnridge J.D., and Coulthard K. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents 25 (2005) 11-25
2. Jain R., and Danziger L.H. Multidrug-resistant acinetobacter infections: an emerging challenge to clinicians. Ann Pharmacother 38 (2004) 1449-1459
3. Michalopoulos A.S., Tsiodras S., Rellos K., Mentzelopoulos S., and Falagas M.E. Colistin treatment in patients with ICU-aquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect 11 (2005) 115-121
4. Evans M.E., Feola D.J., and Rapp R.P. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant Gram-negative bacteria. Ann Pharmacother 33 (1999) 960-967
5. Barnett M., Bushby S.R., and Wilkinson S. Sodium sulphonmethyl derivatives of polymyxins. Br J Pharmacol 23 (1964) 552-574
6. Bergen P.J., Li J., Rayner C.R., and Nation R.L. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 50 (2006) 1953-1958
7. Li J., Milne R.W., Nation R.L., Turnidge J.D., Coulthard K., and Valentine J. Simple method for assaying colistin methanesulfonate in plasma and urine using high-performance liquid chromatography. Antimicrob Agents Chemother 46 (2002) 3304-3307
8. Li J., Milne R.W., Nation R.L., Turnidge J.D., Coulthard K., and Johnson D.W. A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridge and reverse-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 761 (2001) 167-175
9. Li J., Milne R.W., Nation R.L., Turnidge J.D., Smeaton T.C., and Coulthard K. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J Antimicrob Chemother 53 (2004) 837-840
10. Li J., Coulthard K., Milne R., Nation R.L., Conway S., Peckham D., et al. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J Antimicrob Chemother 52 (2003) 987-992
11. Falagas M.E., and Kasiakou S.K. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 40 (2005) 1333-1341
12. Li J., Nation R.L., Turnidge J.D., Milne R.W., Coulthard K., Rayner C.R., et al. Colistin : the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 6 (2006) 589-601
13. Trotman R.L., Williamson J.C., Shoemaker D.M., and Salzer W.L. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis 41 (2005) 1159-1166
14. Li J., Rayner C.R., Nation R.L., Deans R., Boots R., Widdecombe N., et al. Pharmacokinetics of colistin methanesulfonate and colistin in critically ill patient receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother 49 (2005) 4814-4815
15. Jimenez-Mejias M.E., Pichardo-Guerrero C., Marquez-Rivas F.J., Pichardo C., Cuberos L., and Pachon J. Cerebrospinal fluid penetration and pharmacokinetic/pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant Acinetobacter baumannii meningitis. Eur J Clin Microbiol Infect Dis 21 (2002) 212-214
16. Le Brun P.P., de Boer A.H., Mannes G.P., de Fraîture D.M., Brimicombe R.W., Touw D.J., et al. Dry powder inhalation of antibiotics in cystic fibrosis therapy, part 2: inhalation of a novel colistin dry powder formulation: a feasibility study in healthy volunteers and patients. Eur J Pharm Biopharm 54 (2002) 25-32
17. Ratjen F., Rietschel E., Kasel D., Schwiertz R., Starke K., Beier H., et al. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J Antimicrob Chemother 57 (2006) 306-311
18. Martin C., and Gouin F. Les polypeptides. L'antibiothérapie en réanimation, aux urgences et en chirurgie (2000), Arnette, Paris 203-206
19. Montero A., Ariza J., and Corbella X. Efficacy of colistin versus beta-lactams, aminoglycosides, and rifampicin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii. Antimicrob Agents Chemother 46 (2002) 1946-1952
20. Clinical and Laboratory Standards Institution. Performance standards for antimicrobial susceptibility testing. Fifteenth information supplement (M100-S15). Wayne, PA, USA:CLSI,2005.
21. Koch-Weser J., Sidel V.W., Federman E.B., Kanarek P., Finer D.C., and Eaton A.E. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 72 (1970) 857-868
22. Li J., Rayner C.R., and Nation R.L. Colistin-associated acute renal failure revisited. South Med J 98 (2005) 1229-1230
23. Markou N., Apostolakos H., Koumoudiou C., Athanasiou M., Koutouskou A., Alamanos I., et al. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care 7 (2003) 78-83
24. Garnacho-Montero J., Ortiz-Leyba C., Jiménez-Jiménez F.J., Barrero-Almodóvar A.E., García-Garmendia J.L., Bernabeu-WittelI M., et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 36 (2003) 1111-1118
25. Falgalas M.E., and Kasiakou S.K. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 10 (2006) R27
26. Conway S.P., Etherington C., Munday J., Goldman M.H., Strong J.J., and Wootton M. Safety and tolerability of bolus intravenous colistin in acute respiratory exacerbations in adults with cystic fibrosis. Ann Pharmacother 34 (2000) 1238-1242
27. Ledson M.J., Gallagher M.J., Cowperthwaite C., Convery R.P., and Walshaw M.J. Four year's experience of intravenous colomycin in an adult with cystic fibrosis unit. Eur Respir J 12 (1998) 592-594
28. Littlewood J.M., Koch C., Lambert P.A., Høiby N., Elborn J.S., Conway S.P., et al. A ten year review of Colomycin. Respir Med 94 (2000) 632-640
29. Li J., Rayner C.R., Nation R.L., Owen R.J., Spelman D., Tan K.E., et al. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 50 (2006) 2946-2950
30. Levin A.S., Barone A.A., Penço J., Santos M.V., Marinho I.S., Arruda E.A., et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumanni. Clin Infect Dis 28 (1999) 1008-1011
31. Benifla M., Zucker G., Cohen A., and Alkan M. Succesful treatment of Acinetobacter meningitis with intrathecal polymyxin E. J Antimicrob Chemother 54 (2004) 290-292
32. Vasen W., Desmery P., Ilutovich S., and Di Martino A. Intrathecal use of colistin. J Clin Microbiol 38 (2000) 3523
33. Hoiby N., Frederiksen B., and Pressler T. Eradication of early Pseudomonas aeruginosa infection. J Cyst Fibros 4 (2005) 49-54
34. Littlewood J.M., Miller M.G., Ghoneim A.T., and Ramsden C.H. Nebulized Colomycin for early pseudomonas colonization in cystic fibrosis. Lancet 1 (1985) 865
35. Michalopoulos A., Kasiakou S., Mastora Z., Rellos K., Kapaskelis A.M., and Falagas M.E. Aerosolized colistin fort he treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Crit Care 9 (2005) R53-R59
36. Koeman M., van der Ven A.J., Hak E., Joore H.C., Kaasjager K., de Smet A.G., et al. Oral decontamination with chlorhexidine reduces the incidence of ventilator-associated pneumonia. Am J Respir Crit Care Med 173 (2006) 1348-1355
37. Gunderson B.W., Ibrahim K.H., Hovde L.B., Fromm T.L., Reed M.D., and Rotschafer J.C. Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 47 (2003) 905-909
38. Tascini C., Gemignani G., Ferranti S., Tagliaferri E., Leonildi A., Lucarini A., et al. Microbiological activity and clinical efficacy of a colistin and rifampin combination in multidrug-resistant Pseudomonas aeruginosa infections. J Chemother 16 (2004) 282-287
39. Tascini C., Ferranti S., Messina F., and Menichetti F. In vitro and in vivo synergistic activity of colistin, rifampin, and amikacin against a multiresistant Pseudomonas aeruginosa isolate. Clin Microbiol Infect 6 (2000) 690-691
40. Conway S.P., Pond M.N., Watson A., Etherington C., Robey H.L., and Goldman M.H. Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis. Thorax 52 (1997) 987-993